The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K
Аутори:Maksimović, Danijela D.
Mojić, Marija K.
Bulatović, Mirna Z.
Stošić-Grujičić, Stanislava D.
Miljković, Đorđe M.
Mijatović, Sanja A.
Чланак у часопису
МетаподациПриказ свих података о документу
Covalent attachment of NO to the first approved HIV protease inhibitor Saquinavir (Saq-NO) expands the therapeutic potential of the original drug. Apart from retained antiviral activity, the modified drug exerts strong antitumor effects and lower toxicity. In the present study, we have evaluated the sensitivity of different hematological malignancies to Saq-NO. Saq-NO efficiently diminished the viability of Jurkat, Raji, HL-60 and K562 cells. While Jurkat and Raji cells (established from pediatric patients) displayed abrogated proliferative potential, HL-60 and K652 cells (originated from adults) exposed to Saq-NO treatment underwent caspase dependent apoptosis. In addition, similar sensitivity to Saq-NO was observed in mononuclear blood cells obtained from pediatric patients with acute lymphoblastic leukemia (ALL) and adult patients with acute myeloid leukemia (AML). Western blot analysis indicated p70S6 kinase as a possible intracellular target of Saq-NO action. Moreover, the addition of a NO moiety to Lopinavir resulted in improved antitumor potential as compared to the parental compound, suggesting that NO-derived HIV protease inhibitors are a potential new source of anticancer drugs with unique mode of action. (C) 2015 Elsevier Ltd. All rights reserved.
Кључне речи:Saquinavir; Saquinavir-NO; Acute lymphoid leukemia; Acute myeloid leukemia; p70S6 kinase
Извор:Leukemia Research, 2015, 39, 10, 1088-1095